Novo Nordisk Fails Adverse Event Reporting
FDA issued a Warning Letter to Novo Nordisk after an inspection from January 13–February 7, 2025, finding violations of postmarketing adverse drug experience (PADE) reporting requirements under 21 CFR 314.80. The agency cited procedures that allowed rejecting or cancelling serious, unexpected adverse events — including Argus1 case 1331385 involving a stroke on liraglutide — preventing required 15-day reports. The finding obliges Novo Nordisk to correct pharmacovigilance procedures and submit missing reports.
Key Points
- 1Failed to report serious, unexpected postmarketing adverse drug experiences within required 15-day window.
- 2Found written procedures allowed rejecting cases labeled 'unrelated,' conflicting with 21 CFR 314.80 reporting rules.
- 3Practitioners must audit pharmacovigilance and revise SOPs to ensure compliance and timely FDA submissions.
Scoring Rationale
Official FDA enforcement produces high credibility and actionable compliance requirements; impact limited by company-specific scope and sector focus.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems
